aTYR PHARMA (ATYR) Change in Accured Expenses (2014 - 2026)

aTYR PHARMA (ATYR) has 13 years of Change in Accured Expenses data on file, last reported at -$3.5 million in Q1 2026.

• Quarterly Change in Accured Expenses rose 19.78% year-over-year to -$3.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $822000.0 (up 115.13% YoY) and the FY2025 annual result came in at -$33000.0, up 97.54% from the prior year.
• Change in Accured Expenses slipped to -$3.5 million in Q1 2026, from -$536000.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $4.8 million in Q2 2025 to a low of -$4.3 million in Q1 2025.
• A 5-year average of $303764.7 and a median of $216000.0 in 2022 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses soared 935.0% — and 2024, when it sank 11097.37%.
• Tracing ATYR's Change in Accured Expenses over 5 years: stood at $1.9 million in 2022, then jumped by 81.86% to $3.4 million in 2023, then sank by 75.65% to $825000.0 in 2024, then slumped by 164.97% to -$536000.0 in 2025, then sank by 546.83% to -$3.5 million in 2026.
• The last three Change in Accured Expenses figures came in at -$3.5 million (Q1 2026), -$536000.0 (Q4 2025), and $18000.0 (Q3 2025), per Business Quant data.